«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第5期

页码:

616-619

栏目:

综述

出版日期:

2016-04-25

文章信息/Info

Title:

Research progress of β3 adrenergic receptor and myocardial metabolic remodeling of atrial fibrillation

作者:

田静朴; 王小兵; 李为民

（哈尔滨医科大学附属第一医院心内科，黑龙江 哈尔滨 150001）

Author(s):

TIAN Jing-pu;  WANG Xiao-bing;  LI Wei-min

(Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)

关键词:

β3肾上腺素能受体; 心房颤动; 代谢重构

Keywords:

β3-Adrenoceptor;  atrial fibrillation;  metabolic remodeling

分类号:

R541.75

DOI:

-

文献标识码:

A

摘要:

心房颤动（atrial fabrillation，AF）时，心房发生代谢重构，可促进AF的发生及维持，二者相互促进形成恶性循环，可进一步加重AF。研究表明β3肾上腺素能受体（β3-Adrenoceptor，β3-AR）与AF电重构、结构重构密切相关，但关于β3-AR对AF心肌能量代谢重构作用的报道较少。本综述旨在探讨β3-AR与AF心肌能量代谢重构的关系，为临床AF的防治寻找新靶点。

Abstract:

With atrial fibrillation (AF), metabolic remodeling can occur in the atrium and promote the occurrence and persistence of AF. The two mutually promote, forming a vicious spiral, further aggravating the AF. Research shows that β3 adrenergic receptor (β3-AR) is closely related to the myocardial electrical remodeling and structural remodeling of AF, but there have been relatively few reports concerning the effect of β3-AR on myocardial energy metabolism remodeling of AF. This review explores the relationship between β3-AR and myocardial energy metabolism remodeling of AF in order to find new targets for clinical treatment of AF.

参考文献/References

[1]Gauthier C1,Sèze-Goismier C,Rozec B. Beta 3-adrenoceptors in the cardiovascular system[J].Clin Hemorheol Microcirc,2007,37(1-2):193-204.
[2]Rozec B,Erfanian M,Laurent K,et al.Nebivolol, a vasodilation selective beta1-blocker,is abeta3-adrenoceptor agonist in the nonfailing transplanted human heart[J].J Am Coll Cardiol,2009, 53(17):1532-1538.
[3]Aragon JP,Condit ME,Bhushan S,et al.Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthaseactivation[J].J Am Coll Cardiol,2011,58(25):2683-2691.
[4]Mulder B,van Veldhuisen D,Crijns H,et al.Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation:insights from SENIORS[J].Eur J Heart Fail,2012,14(10):1171-1178.
[5]Yu J,Li W,Li Y,et al.Activation of β3-adrenoceptor promotes rapidpacing-induced atrial electrical remodeling in rabbits[J].Cell Physiol Biochem,2011,28(1):87-96.
[6]Sheng L,Shen Q,Huang K,et al.Up-regulation of β3-adrenergic receptorscontributes to atrial structural remodeling in rapid pacing induced atrial fibrillation canines[J].Cell Physiol Biochem,2012,30(2):372-381.
[7]郭彦青,李艳芳.β肾上腺素受体研究进展[J].中华老年心脑血管病杂志,2013,12(15):1331-1332.
[8]Moens AL,Yang R,Watts VL,et al.Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system[J].J Mol Cell Cardiol,2010,48(6):1088-1095.
[9]Napp A,Brixius K,Pott C,et al.Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium[J].J Card Fail,2009,15(1):57-167.
[10]Bundgaard H,Liu CC,Garcia A,et al.β(3)adrenergic stimulation of the cardiac Na+-K+pump by reversal ofan inhibitory oxidative modification[J].Circulation,2010,122(25):2699-2708.
[11]Coman OA,P?unescu H,Ghit? I,et al.Beta 3 adrenergic receptors:molecular, histological, functional and pharmacological approaches[J].Rom J Morphol Embryol,2009,50(1):169-179.
[12]Kong YH,Zhang Y,Li N,et al.Association between beta3-adrenergic receptor and oxidative stress in chronic heart failure rats[J].Zhonghua Xin Xue Guan Bing Za Zhi,2010,38(5):435-439.
[13]Aksnes TA,Schmieder RE,Kjeldsen SE,et al.Impact of new-onset diabetes mellitus on development of AF and heart failure in high-risk hypertension( from the VALUE Trial)[J].Am J Cardiol,2008,101:634-638.
[14]Liu Y,Geng J,Li Y,et al.β3-adrenoceptor mediates metabolic protein remodeling in a rabbit model of tachypacing-induced atrial fibrillation[J].Cell Physiol Biochem,2013,32(6):1631-1642.
[15]Horowitz JD,Chirkov YY,Kennedy JA,et al.Modulation of myocardial metabolism: an emerging therapeutic principle[J].Curr Opin Cardiol,2010,25(4):329-334.
[16]Zhou L,Zhang P,Cheng Z,et al.Altered circadian rhythm of cardiac beta3-adrenoceptor activity following myocardial infarction in the rat[J].Basic Res Cardiol,2011,106(1):37-50.
[17]Sorrentino SA,Doerries C,Manes C,et al.Nebivolol exerts benificial effects on endothelial function,early endothelial progrnitor cells,myocardial neovascularization, and left ventricular dysfunction earky after myocardial infarction beyond cnventional beta1-ARblockade[J].J Am Coll Cardiol,2011,57(5):601-611.
[18]左瑞平,于佳慧,赵 静,等.兴奋β3受体对快速心房起搏家兔心房肌细胞 I(Ca, L)的影响[J].心脏杂志,2013,25(1):6-9.
[19]Niu X,Watts VL,Cingolani OH,et al.Cardioprotective effect of beta-3 adrenergic receptor agonism:role of neuronal nitric oxide synthase[J].J Am Coll Cardiol,2012,59(22):1979-1987.
[20]Moens AL,Leyton-Mange JS,Niu X,et al.Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor[J].J Mol Cell Cardiol,2009,47(5):576-585.
[21]Calvert JW,Condit ME,Aragon JP,et al.Exercise protects against myocardial ischemia-reperfusion injury via stimulation of β(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols[J].Circ Res,2011,108(12):1448-1458.
[22]Mayyas F,Sakurai S,Ram R,et al.Dietaryω3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model[J].Cardiovasc Res, 2011,89(4):852-861.
[23]Schotten U,Verheule S,Kirchhof P,et al.Pathophysiological mechanisms of atrial fibrillation:a translational appraisal[J].Physiological Reviews,2011,91(1):265-325.
[24]Nishijima Y,Sridhar A,Bonilla I,et al.Tetrahydrobiopterin depletion and NOS2 uncoupling contribute toheart failure-induced alterations inatrial electrophysiology[J].Cardiovasc Res,2011,91(1):71-79.
[25]Antoniades C,Demosthenous M,Reilly S,et al.Myocardial redox state predicts in-hospital clinical outcomeafter cardiac surgery effects of shortterm pre-operative statin treatment[J].J Am Coll Cardiol,2012,59(1):60-70.
[26]Negi S,Sovari AA,Dudley SC Jr.Atrial fibrillation:the emerging role of inflammation and oxidative stress[J].Cardiovasc Hematol Disord Drug Targets,2010,10(4):262-268.
[27]Sovari AA,Dudley SC Jr.Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation[J].Front Physiol,2012,3:311.
[28]Bonilla IM,Sridhar A,Gy?rke S,et al.Nitric oxide synthases and atrial fibrillation[J].Front Physiol,2012,23(3):105.
[29]Van BM,Van NFA.PPARs as therapeutic targets in cardiovascular disease[J].Expert Opin Ther Targets, 2010, 14(10):1029-1045.
[30]Jing L,Zhou LJ,Li WM,et al.Carnitine regulates myocardial metabolism by Peroxisom Proliferator-Activated Receptor-alpha(PPAR-α)in alcoholic cardiomyopathy[J].Med Sci Monit,2011,17(1):BR1-BR9.
[31]Rowe G,Jiang A,Arany Z.PGC-1 coactivators in cardiac development and disease[J].Circ Res,2010,107(7):825-838.
[32]Xu D,Murakoshi N,Igarashi M,et al.PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model[J].J Cardiovasc Electrophysiol,2012,23(2):209-217.

备注/Memo

备注/Memo:

收稿日期：2015-01-07.
通讯作者：李为民，教授，主要从事冠心病介入治疗 Email:Liweimin_2009@163.com 作者单位：田静朴，硕士生 Email：meng_1988330@163.com

常用功能

更新日期/Last Update: 2016-04-13